Trial reportNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology2021
MDMA-induced changes in within-network connectivity contradict the specificity of these alterations for the effects of serotonergic hallucinogens.
Trial report in Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 42 citations in OpenAlex.
- Drug-drug interactions between psychiatric medications and MDMA or psilocybin: a systematic review.Psychopharmacology · 2022Pooled it
- Spatiotemporal mapping of brain organisation following the administration of 2C-B and psilocybin.Molecular psychiatry · 2026Trial
- Large-scale brain connectivity changes following the administration of lysergic acid diethylamide, d-amphetamine, and 3,4-methylenedioxyamphetamine.Molecular psychiatry · 2025Trial
- Neurobiological Correlates of Psychedelic Experiences and Psychedelic-Associated Adverse Effects.Current topics in behavioral neurosciences · 2026Review
- Dissociable effects of LSD and MDMA on striato-cortical connectivity in healthy subjects.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026Article
- Psychedelic therapy: bridging neuroplasticity, phenomenology, and clinical outcomes.Frontiers in psychiatry · 2025Article
- Direct serotonin release in humans shapes aversive learning and inhibition.Nature communications · 2024Article
- Psilocybin desynchronizes the human brain.Nature · 2024Article
- Exploring psychedelic-assisted therapy in the treatment of functional seizures: A review of underlying mechanisms and associated brain networks.Journal of psychopharmacology (Oxford, England) · 2024Review
- Alterations in brain network connectivity and subjective experience induced by psychedelics: a scoping review.Frontiers in psychiatry · 2024Article
- Psilocybin desynchronizes brain networks.medRxiv : the preprint server for health sciences · 2023Article
- Postpartum depression: A role for psychedelics?Journal of psychopharmacology (Oxford, England) · 2022Review
- Classic Psychedelic Drugs: Update on Biological Mechanisms.Pharmacopsychiatry · 2022Article
- Psilocin acutely alters sleep-wake architecture and cortical brain activity in laboratory mice.Translational psychiatry · 2022Article
- The Kappa Opioid Receptor and the Sleep of Reason: Cortico-Subcortical Imbalance Following Salvinorin-A.The international journal of neuropsychopharmacology · 2022Article
- Lasting effects of a single psilocybin dose on resting-state functional connectivity in healthy individuals.Journal of psychopharmacology (Oxford, England) · 2022Article
- Altered brain activity and functional connectivity after MDMA-assisted therapy for post-traumatic stress disorder.Frontiers in psychiatry · 2022Article
- Psychedelics and Consciousness: Distinctions, Demarcations, and Opportunities.The international journal of neuropsychopharmacology · 2021Review
- Psychedelic Therapy's Transdiagnostic Effects: A Research Domain Criteria (RDoC) Perspective.Frontiers in psychiatry · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
It has been reported that serotonergic hallucinogens like lysergic acid diethylamide (LSD) induce decreases in functional connectivity within various resting-state networks. These alterations were seen as reflecting specific neuronal effects of hallucinogens and it was speculated that these shifts in connectivity underlie the characteristic subjective drug effects. In this study, we test the hypothesis that these alterations are not specific for hallucinogens but that they can be induced by monoaminergic stimulation using the non-hallucinogenic serotonin-norepinephrine-dopamine releasing agent 3,4-methylenedioxymethamphetamine (MDMA). In a randomized, placebo-controlled, double-blind, crossover design, 45 healthy participants underwent functional magnetic resonance imaging (fMRI) following oral administration of 125 mg MDMA. The networks under question were identified using independent component analysis (ICA) and were tested with regard to within-network connectivity. Results revealed decreased connectivity within two visual networks, the default mode network (DMN), and the sensorimotor network. These findings were almost identical to the results previously reported for hallucinogenic drugs. Therefore, our results suggest that monoaminergic substances can induce widespread changes in within-network connectivity in the absence of marked subjective drug effects. This contradicts the notion that these alterations can be regarded as specific for serotonergic hallucinogens. However, changes within the DMN might explain antidepressants effects of some of these substances.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.